Daily News: Disease

BRIEF: Generic-drug delays blamed for high costs

Sacramento Bee (CA)

07-31-13

July 31--Californians with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 key drugs, according to a report by the California Public Interest Research Group and Boston-based Community Catalyst.

The report, titled "Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers," claims the affected drugs have been subject to an industry practice called "pay for delay," in which brand-name pharmaceutical companies pay off generic drug manufacturers to keep lower-cost equivalents off the market.

For more details, see www.calpirg.org.

___

(c)2013 The Sacramento Bee (Sacramento, Calif.)

Visit The Sacramento Bee (Sacramento, Calif.) at www.sacbee.com

Distributed by MCT Information Services

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.